Table 1

Clinical data (Part A contains data of patients donating solid tumours, while part B contains a list of samples obtained from pleural effusions)

Sample number	Mutations	Diagnosis	T	N	M	Intervention	Date of sampling	Clinical therapy	In vitro	Type of treatment	Beginning of therapy	End of therapy	Treatment before/after sampling	RECIST	RECIST date	PD-L1
A. Patient data of solid tumours
Solid tumors
1	KRAS	NSCLC-Adenocc.	pT1b	pN1	Mx	Complete tumour resection	27 October 2015	Observation	–		27 October 2015	22 May 2017	After	PD	29 March 2017	>50% (Positive)
			pT1b	N3	M1a			Cisplatin + pemetrexed	Tested	Palliative	23 May 2017	09 August 2017	After	SD	25 August 2017
			T3	N3	M1c			Pemetrexed mono	Tested	Palliative	17 October 2017	28 November 2017	After	PD	14 December 2017
2	WT	NSCLC-Adenocc.	pT2a	N1	Mx	Complete tumour resection	01 December 2015	Cisplatin + vinorelbine	Tested	Adjuvant	06 January 2016	24 June 2016	After	SD	–	Negative
3	KRAS	NSCLC-Adenocc.	pT3	pN2	Mx	Complete tumour resection	28 April 2016	Observation	–		29 April 2016	29 June 2016	After	PD	26 May 2016	Negative
3			pT3	pN2	M1a			Cisplatin + pemetrexed	Tested	Palliative	30 June 2016	30 June 2016	After	PD	05 July 2016
4	KRAS	NSCLC-Adenocc.	pT3	N0	M1b	Complete tumour resection	03 May 2016	Cisplatin + gemcitabine	Tested	Adjuvant	07 July 2016	08 August 2016	After	SD	06 September 2017	Negative
5	KRAS	NSCLC-Adenocc.	pT3a	N1	Mx	Complete tumour resection	26 June 2016	Cisplatin + vinorelbine	Tested	Adjuvant	08 August 2016	30 September 2016	After	SD	27 April 2017	Negative
6	KRAS	NSCLC-Adenocc.	pT2a	pN2	M1c	Complete tumour resection	12 September 2016	Carboplatin + gemcitabine	Tested	Adjuvant	12 October 2016	07 December 2016	After	PD	24 January 2017	<1% (Negative)
7	KRAS	NSCLC - Adeno cc	pT2	pN1	Mx	Complete tumour resection	05 December 2016	Cisplatin+pemetrexed	Tested	Adjuvant	21 February 2017	03 May 2017	After	SD	23 May 2017
8		NSCLC - Adeno cc	pT2a	pNx	Mx	Complete tumour resection	05 January 2017	Carboplatin – paclitaxel	Tested	Adjuvant	28 March 2017	15 June 2017	After	SD	20 July 2017
9	KRAS	NSCLC - Adeno cc	pT2	pN1	Mx	Complete tumour resection	14 December 2015	Cisplatin + vinorelbine	Tested	Adjuvant	18 February 2016	08 April 2016		SD	08 July 2016
10	EGFR	NSCLC - Adeno cc	pT2a	pN2	Mx	Complete tumour resection	19 December 2016	Cisplatin + vinorelbine	Tested	Adjuvant	09 February 2017	02 March 2017	After	SD	20 March 2017
10			pT2a	pN2	Mx			Erlotinib mono	Tested	Palliative	18 October 2017	13 August 2018	After	PD	13 August 2018
B. Patient data of pleural effusion donors
Pleural effusions
1	EGFR	NSCLC - Adeno cc	T3	Nx	M1b	Thoracic aspiration	20 February 2017	Gefitinib	Tested	Palliative	04 February 2015	14 June 2017	During	PD	14 June 2017	Negative
2	KRAS	NSCLC - Adeno cc	T2a	N2	M1a	Thoracic aspiration	06 May 2017	Cisplatin + pemetrexed	Tested	Palliative	20 May 2016	28 July 2017	After	SD	04 August 2016	Negative
2			T2a	N2	M1a			Pemetrexed mono	Tested	Palliative	19 September 2016	03 November 2016	After	PD	17 November2016
3	EGFR	NSCLC - Adeno cc	T4	N2	M1	Thoracic aspiration	25 February 2016	Erlotinib mono	Tested	Palliative	26 January 2016	28 July 2016	Before	PD	13 July 2017	Negative
			T4	N2	M1			Osimertinib	-	Palliative	31 August 2016	30 June 2017	After	PD	01 August 2017
			T4	N2	M1			Carboplatin + paclitaxel	Tested	Palliative	09 August 2017	30 August 2017	After	PD	18 September 2017
			T4	N3	M1c			Pemetrexed mono	Tested	Palliative	11 October 2017	05 January 2018	After	PD	25 January 2018
4	WT	NSCLC - Adeno cc	T2a	N2	M1a	Thoracic aspiration	27 July 2016	Carboplatin + paclitaxel	Tested	Palliative	15 June 2016	26 August 2016	During	PD	08 September 2016	Negative
4			T4	N3	M1b			Erlotinib mono	Tested	Palliative	04 October 2016	12 December 2016	After	PD	12 December 2016

The information ranges from the actual method of obtaining the sample, mutation analysis, diagnosis, staging (TNM=tumour, node, metastasis status) of the disease and applied treatment or treatments and clinical responses.
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-L1, programmed death ligand-1; RECIST, Response Evaluation Criteria In Solid Tumours; SD, stable disease.